بازدیدکنندگان
امروز: 141
ديروز:781
اين هفته: 3781
هفته‌ي گذشته: 4200
اين ماه: 14087
ماه گذشته: 2314
افراد آنلاين:1
اعضا ی آنلاین : 0
مهمان آنلاین : 1

فعالیتهای تحقیقاتی دکتر سیده هدی علوی زاده

 

 

Seyedeh Hoda Alavizadeh (Pharm. D, Ph.D.)

 

Mailing address:                                                                 

University Complex, Mashhad University of Medical Sciences (MUMS),

 Mashhad, Iran

P.O. Box: 91886 17871

E-mail:

این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید ,    این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

Phone                      +98 513-1801334

Cell Phone:                +989153024312

 

Current position: Assistant professor of Pharmaceutical Nanotechnology at School of Pharmacy, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran

 

Post-Graduate Studies (Ph.D. Pharmaceutical nanotechnology)

Mashhad University of Medical Sciences (MUMS), Mashhad, Iran (2011-2016)

 

Ph.D. Thesis Title:  Formulation and characterization of temperature-sensitive nanoliposomal cisplatin targeted with anti-Her-2/neu affibody and evaluation of their antitumor effects with local hyperthermia in vitro and in vivo in mice model bearing tumor

 

Supervisors: Mahmoud Reza Jaafari, Pharm. D., Ph.D.; Ali Badiee, Pharm. D., Ph.D.; Shiva Golmohammadzadeh, Pharm. D., Ph.D.

Synopsis:

 Developed novel tumor microenvironment-responsive liposome nanoparticles for targeted breast and colon cancer drug delivery

 Characterized physicochemical properties of the nanoparticles loaded with cisplatin in terms of size, surface morphology, drug loading, serum stability & drug release profile

 Evaluated impact of the nanomedicines on cell proliferation, cellular uptake and anti-tumor efficacy in mice tumor model.

 

Graduate Studies (Pharm. D.)

Mashhad University of Medical Sciences (MUMS), Iran (2004 - 2010)

Degree Course: Pharmacy (Major: Pharmaceutical Sciences; Cumulative GPA: 17.85/20)           

 

Pharm. D. Thesis Title: Evaluation of lesion development and type of immune response generated in mice inoculated with L. major mixed with LPD nanoparticles containing CpG ODN (Written and available in English)

 

 Refereed Journal Articles

 

 1- Firouzmand H, Sahranavard M, Badiee A, Khamesipour A, Alavizadeh SH, Samiei A, Soroush D, Tavassoti KM, Mahboudi F, Jaafari MR. The role of LPD-nanoparticles containing recombinant major surface glycoprotein of Leishmania (rgp63) in protection against leishmaniasis in murine model. Immunopharmacology and immunotoxicology. 2017 Dec 6:1.

(IF: 1.203)

2-  Iman M, Huang Z, Alavizadeh SH, Szoka Jr FC, Jaafari MR. Biodistribution and In Vivo Antileishmanial Activity of 1, 2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B. Antimicrobial agents and chemotherapy. 2017 Aug 24;61(9).

(IF: 4.476)

 3- Balarastaghi S, Khashaiarmanesh Z, Makhdoumi P, Alavizadeh SH, Sameie Moghadam Z, Shirani K, Karimi G. Determination of toxic element levels (lead and cadmium) in commonly used cosmetic products in Iran. Toxin Reviews. 2017 May 24:1-6.

(IF: 0.647)

 4- Hojatizade M, Badiee A, Khamesipour A, Mirshafiey A, Akhtari J, Mehravaran A, Alavizadeh SH, Abbasi A, Saberi Z, Nikpoor AR, Jaafari MR. DDA/TDB liposomes containing soluble Leishmania major antigens induced a mixed Th1/Th2 immune response in BALB/c mice. Nanomedicine Journal 2017 Apr 1; 4(2):71-82.

5- Alavizadeh SH, Gheybi F, Nikpoor AR, Badiee A, Golmohammadzadeh S, Jaafari MR., Therapeutic Efficacy of Cisplatin Thermosensitive Liposomes upon Mild Hyperthermia in C26 Tumor Bearing BALB/c Mice. Molecular Pharmaceutics 2017 Mar 6; 14(3):712-721.

(IF: 4.44)

 6- Abbaszadegan S, Hosseinzadeh H , Alavizadeh SH , Mohamadi M, Abbasi  A , Jaafari  MR., Characterization and anti-tumor activity of PEGylated nanoliposomes containing safranal in mice bearing c26 colon carcinoma. International Journal of Pharmaceutical Sciences and Research 2016 Nov, 7(11): 4379-4386.

(IF: 1.11)

 7- Fakhraee F, Badiee A, Alavizadeh SH, Jalali SA, Chavoshian O, Khamesipour A, Mahboudid F, Jaafari MR. Coadminstration of L. major amastigote class I nuclease (rLmaCIN) with LPD nanoparticles delays the progression of skin lesion and the L .major dissemination to the spleen in BALB/c mice- based experimental setting. Acta Tropica 2016 July, 159: 211-218.

(IF: 2.27)

 8- Alavizadeh SH, Soltani F, Ramezani M., Recent Advances in Immunoliposome-Based Cancer Therapy. Current Pharmacology Report, 2016 May; 2 (3): 129-141.

 9- Akhtari J, Rezayat SM,  Teymouri M, Alavizadeh SH, Badiee A , Gheybi F, Hojatizadeh M, Jalali A, Jaafari MR. Targeting, bio distributive and therapeutic characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. International Journal of Pharmaceutics, 2016 May; 505 (1-2): 89-95.

(IF: 3.994)

 10- Alavizadeh SH, Akhtari J, Badiee A, Golmohammadzadeh Sh, Jaafari MR., HER2 affibody-targeted cisplatin liposome inhibits the growth of HER2-expressing breast tumor models. Expert Opinion on Drug Delivery, 2016 Mar; 13(3):325-36.

(IF: 5.434)    

 11- Marzban E, Alavizadeh SH, Ghiadi M, Khoshangosht M, Khashayarmanesh Z, Abbasi A, Jaafari MR., Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: in vitro and in vivo studies. Colloids and Surfaces B: Biointerfaces, 2015 Nov, 136; 885-891 (listed as co-corresponding author).

 (IF: 4.152)

 12- Alavizadeh SH, Badiee A, Golmohammadzadeh Sh, Jaafari MR., The influence of phospholipid on the physicochemical properties and antitumor efficacy of liposome encapsulating cisplatin in mice bearing C26 colon carcinoma. International Journal of Pharmaceutics. 2014 Oct, 473; 326-333.

(IF: 3.65)

 13- Alavizadeh SH, Hosseinzadeh H., Bioactivity assessment and toxicity of crocin: a comprehensive review. Food and Chemical Toxicology. 2014 Feb; 64: 65-80.

(IF: 2.895)

(Listed among the 1% top papers of the World in 2016 as reported by Essential Science Indicator of Thompson Reuter ISI)

14- Firouzmand H, Badiee A, Khamesipour A, Heravi Shargh V, Alavizadeh SH, Abbasi A, Jaafari MR., Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Tropica. 2013 Dec; 128(3):528-35.(IF: 2.27)

15- Rastgoo M, Hosseinzadeh H, Alavizadeh SH, Abbasi A, Ayati Z, Jaafari MR., Antitumor activity of PEGylated nanoliposomes containing crocin in mice bearing C26 colon carcinoma. Planta Medica. 2013 Apr; 79(6):447-51.(IF: 2.152)

16- Alavizadeh SH, Badiee A, Khamesipour A, Jalali SA, Firouzmand H, Abbasi A, Jaafari MR., The role of liposome-protamine-DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by Leishmania major in BALB/c mice. Experimental Parasitology. 2012 Nov; 132(3):313-9(IF: 1.638)

 

Conference Presentations

1- Seyedeh Hoda Alavizadeh, Fatemeh Gheybi, Amin Reza Nikpoor, Mahmoud Reza Jaafari, Optimizing stealth cisplatin liposomes by using mild hyperthermia and triggered content release in vivo. ILS/LRD Liposome Advances Conference, September 16-18 2017, Athens, Greece (Platform presentation)

2-Seyedeh Hoda Alavizadeh, Mahmoud Reza Jaafari, Optimizing cisplatin thermosensitive liposomes to improve therapeutic efficacy at mild hyperthermia in C26 tumor bearing BALB/c mice. The European Summit for Clinical Nanomedicine and Targeted Medicine, the Translation to Knowledge Based Nanomedicinem, 10th Conference and Exhibition, May 7-10, 2017, Basel, Switzerland (Poster presentation and small speech) (Awarded Best Poster Presentation).

3-Seyedeh Hoda Alavizadeh, Mahmoud Reza Jaafari, Anti-cancer activity of anti-HER2 affisome containing cisplatin in animals with breast cancer. 1ST International Nastaran Cancer Symposium,October 1st 2015, Mashhad, Iran (Poster presentation)

4-Seyedeh Hoda Alavizadeh, Mahmoud Reza Jaafari, Targeted delivery of anti-HER2 affibody conjugated sterically stabilized cisplatin liposome in HER2 receptor-expressing breast cancer models. The European Summit for Clinical Nanomedicine and Targeted Medicine, the Translation to Knowledge Based Nanomedicinem, 8th Conference and Exhibition, June 28-July 1, 2015, Basel, Switzerland (Poster presentation and small speech).

5-Seyedeh Hoda Alavizadeh, Ali Badiee, Shiva Golmohammadzadeh, Mahmoud Reza Jaafari, The influence of bilayer composition on the physicochemical properties and anti-tumor efficacy of liposome encapsulating cisplatin in mice bearing C26 colon carcinoma, The First Middle East & The 6th Iranian Control Release Conference, February 25-27, 2014, Tehran, Iran (Platform presentation).

6-Seyedeh Hoda Alavizadeh, Badiee, A, Khamesipour, A, Jalali, A, Tavassoti Kheiri, M, Barkhordari, F, Mahboudi, F, Jaafari, MR. Preparation and characterization of LPD nanoparticles containing rgp63 and rLmaCIN as a vaccine against cutaneous leishmaniasis, 13th Iranian Pharmaceutical Sciences Congress, 3-6 september 2012, Isfehan, Iran, Research in Pharmaceutical Sciences, 2012;7(5); (Poster presentation) (Awarded Best Poster Presentation).

7-Seyedeh Hoda Alavizadeh, Mahmoud Reza. Jaafari, Ali Badiee, Ali Khamesipour, Amir Jalali, Azam Abbasi, Evaluation of lesion development and type of immune response generated in mice inoculated with L. major mixed with LPD nanoparticles containing CpG ODN, 3rd Conference on Nanostructures, March 10-12, 2010, Sharif University of Technology, International Campus, Kish Island, Iran.( Platform presentation).

8-Seyedeh Hoda Alavizadeh, Ali Badiee, Mahmoud Reza Jaafari, Lipid-Protamine-DNA (LPD) nanoparticles as a vaccine delivery system for cancer immunotherapy, The Specialized Congress and International Exhibition of Nanomedicine, Nanobiotechnology, Nanobiosensors and Nanomaterials, July 14-16, 2009, Mashhad, Iran, Iran J Basic Med Sci, Vol. 12, No. 2, (Poster Presentation).

 

Honors and awards

 1- Fellowship of CLINAM foundation for The European Summit for Clinical Nanomedicine 2017 (10th CLINAM 2017) Basel- Switzerland.

2- Poster presentation award in the European Summit for Clinical Nanomedicine and Targeted Medicine, the Translation to Knowledge Based Nanomedicinem, 10th Conference and Exhibition, May 7-10, 2017, Basel, Switzerland.

3- Listed one paper among the 1% top papers of the World as reported by Essential Science Indicator of Thompson Reuter ISI in 2016 and the first hot paper in Mashhad University of Medical Sciences [Alavizadeh SH, Hosseinzadeh H. Bioactivity assessment and toxicity of crocin: a comprehensive review. Food Chem Toxicol. 2014;64:65-80].

4- Ph.D student award in the field of research in Research Festival of School of Pharmacy, Mashhad, 2014

5- The top research paper in Research Festival of School of Pharmacy, Mashhad, 2014

6- Ph.D student award in the field of research in Research Festival of School of Pharmacy, Mashhad, 2013

7- The top research paper in Research Festival of School of Pharmacy, Mashhad, 2013

8- The best poster presentation award in 13 th Iranian Pharmaceutical Scienses Congress, Isfahan, Iran, 2012

 

Skills

  • Engineering various types of lipid-based nanoparticles
  • Nano-purification (chromatographic, centrifugation, or filtration techniques)
  • Characterization of nanoparticles with analytical techniques (spectrophotometry, DLS/ELS, HPLC, SEM/TEM, freeze-drying, protein/phospholipid assays, etc.)
  • Cell biology: expertise in cell counting, culture and cryopreservation; cellular apoptosis MTT & MTS cytotoxicity assay
  • Cell extract protein purification and immunoblotting
  • ELISA (e.g. cytokine and IgG quantitation)
  • Biodistribution study
  • SDS-PAGE
  • Atomic absorption spectroscopy
  • TLC

 

Research interests

 

  • Targeted drug delivery for cancer therapy, vaccine delivery systems against leishmaniasis, triggered release liposome-based delivery systems

 

Teaching Experience

Pharmacy School, Mashhad University of Medical Sciences (MUMS) (2017-2018)

Characterization of lipid based nanoparticles, targating cancer environment, triggered release nanoparticulate delivery system.

 

Languages

Fluent English (MCHE grade (82/100), IBT TOEFL (105/120)

French (DELF B1)

 

Referees:

 

Dr Mahmoud Reza Jaafari

Professor

School of Pharmacy, Mashhad University of Medical Sciences (MUMS).

Mashhad – Iran

Email: این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

 

Dr Hossein Hosseinzadeh

Professor

School of Pharmacy, Mashhad University of Medical Sciences (MUMS).

Mashhad – Iran

Email:   این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید

 

 

 

 

 

 

دانشگاه علوم پزشکی مشهد | Mashhad University of Medical Sciences | جامعة مشهد للعلوم الطبية
تمام حقوق مادی و معنوی این سایت مربوط به دانشگاه علوم پزشکی مشهد می باشد. هرگونه کپی برداری از مطالب آن تنها با ذکر منبع بلامانع است.